Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Licensed influenza vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

NCT05163847
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
65 Years to 85 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350
View directory record Official record
Conditions
Healthy Adults
Interventions
LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
Device · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus QIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 17 Years
Enrollment
2,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Madera, California • Ontario, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Novartis H1N1 Vaccine in Pregnant Women

NCT00992719
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 7, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
View directory record Official record
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 7, 2026, 2:50 AM EDT
Completed No phase listed Observational

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

NCT01484522
View directory record Official record
Conditions
HIV-1 Infection, H1N1, Influenza, Flu
Interventions
FluMist, Fluvirin, Fluzone
Biological
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Months to 25 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Quadrivalent Influenza Vaccine Among Children

NCT01240746
View directory record Official record
Conditions
Influenza
Interventions
Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
4,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
67
States / cities
Dothan, Alabama • Chandler, Arizona • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462
View directory record Official record
Conditions
Influenza
Interventions
Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Quadrivalent Influenza Vaccine Among Adults

NCT01218646
View directory record Official record
Conditions
Influenza
Interventions
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
12
States / cities
Hoover, Alabama • South Miami, Florida • Springfield, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Afluria
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
14
States / cities
Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 7, 2026, 2:50 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

NCT07805707
View directory record Official record
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
54,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
161
States / cities
Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

NCT01831934
View directory record Official record
Conditions
MELAS Syndrome
Interventions
Fluzone®
Biological
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

NCT00782431
View directory record Official record
Conditions
Influenza
Interventions
Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853
View directory record Official record
Conditions
Healthy Adults
Interventions
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2007 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

NCT02914275
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 59 Months
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240
View directory record Official record
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

NCT01052480
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Anti-Influenza Immune Plasma, Standard Care
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
35
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response Following Seasonal Influenza Vaccination

NCT03163342
View directory record Official record
Conditions
Influenza
Interventions
Licensed seasonal influenza vaccine
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

NCT04785794
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Sing2016 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 7, 2026, 2:50 AM EDT